Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000036031 | SCV000059683 | uncertain significance | not specified | 2018-05-21 | criteria provided, single submitter | clinical testing | Variant classified as Uncertain Significance - Favor Benign. The p.Asp178Asn var iant in MYL3 has been reported in 3 individuals with hypertrophic cardiomyopathy (Weissler-Snir 2017, LMM Data), but has also been identified in 0.14% (44/30782 ) of South Asian chromosomes by the Genome Aggregation Database (gnomAD, http:// gnomad.broadinstitute.org/; dbSNP rs145520567). This variant is also reported in ClinVar (Variation ID 43128). Computational prediction tools and conservation a nalysis suggest that the p.Asp178Asn variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, wh ile the clinical significance of the p.Asp178Asn variant is uncertain, its frequ ency in the general population suggests that it is more likely to be benign. ACM G/AMP Criteria applied: PP3, PS4_Supporting, BS1. |
Gene |
RCV000587491 | SCV000208891 | uncertain significance | not provided | 2022-12-27 | criteria provided, single submitter | clinical testing | Reported in one individual from a cohort with clinically confirmed HCM (Weissler-Snir et al., 2017) and in two patients from the Framingham and Jackson Heart Study cohorts (Bick et al., 2012); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 22958901, 29420653, 28193612, 35653365) |
Illumina Laboratory Services, |
RCV000262754 | SCV000444746 | uncertain significance | Hypertrophic cardiomyopathy | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000262754 | SCV000549162 | likely benign | Hypertrophic cardiomyopathy | 2025-01-26 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000587491 | SCV000696365 | likely benign | not provided | 2016-01-25 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000769163 | SCV000900538 | benign | Cardiomyopathy | 2021-03-24 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000769163 | SCV000904646 | likely benign | Cardiomyopathy | 2019-11-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002345285 | SCV002640800 | likely benign | Cardiovascular phenotype | 2019-10-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |